Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Ivor Royston | M | 79 | 8 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Cynthia Tsai | F | 67 | 3 years | |
| Kimberly D. C. Trapp | F | 65 |
Lumera Corp.
 Lumera Corp. Packaged SoftwareTechnology Services Lumera Corp. develops proprietary polymer materials and products for a broad range of applications. The company designs proprietary molecular structures and polymer compounds for a broad range of electro-optic, bioscience, RF and specialty nanotechnology applications. The company also has developed proprietary processes for fabricating such devices. Lumera Corp. is headquartered in Bothell, WA. | 11 years |
| Bruce A. Cohen | M | 71 | 4 years | |
| Julie Tipton | F | 54 | 3 years | |
| Sharon Tetlow | F | 64 |
Cell Genesys, Inc.
 Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | 4 years |
| Frank W. Schneider | M | 81 | 7 years | |
| Dawn Casterson | F | 59 | - | |
| Neil Miotto | M | 78 | 9 years | |
| Mitchell Finer | M | 65 |
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | 10 years |
| Charles Judso | M | 80 |
Lumera Corp.
Lumera Corp. Packaged SoftwareTechnology Services Lumera Corp. develops proprietary polymer materials and products for a broad range of applications. The company designs proprietary molecular structures and polymer compounds for a broad range of electro-optic, bioscience, RF and specialty nanotechnology applications. The company also has developed proprietary processes for fabricating such devices. Lumera Corp. is headquartered in Bothell, WA. | 7 years |
| Jeff Parsons | M | - | - | |
| John J. Schembri | M | 62 |
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | 3 years |
| Donald Guthrie | M | 68 |
Lumera Corp.
Lumera Corp. Packaged SoftwareTechnology Services Lumera Corp. develops proprietary polymer materials and products for a broad range of applications. The company designs proprietary molecular structures and polymer compounds for a broad range of electro-optic, bioscience, RF and specialty nanotechnology applications. The company also has developed proprietary processes for fabricating such devices. Lumera Corp. is headquartered in Bothell, WA. | 4 years |
| Mark C. Platshon | M | - | - | |
| Helene F. Jaillet | M | - |
Lumera Corp.
Lumera Corp. Packaged SoftwareTechnology Services Lumera Corp. develops proprietary polymer materials and products for a broad range of applications. The company designs proprietary molecular structures and polymer compounds for a broad range of electro-optic, bioscience, RF and specialty nanotechnology applications. The company also has developed proprietary processes for fabricating such devices. Lumera Corp. is headquartered in Bothell, WA. | - |
| Stephen Johnson | M | - | - | |
| Douglas L. Swenson | M | - | - | |
| Lesley A. Stolz | M | 60 |
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | 1 years |
| Jennifer Cook Williams | F | 53 |
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | 9 years |
| Raluca Dinu | M | 50 |
Lumera Corp.
Lumera Corp. Packaged SoftwareTechnology Services Lumera Corp. develops proprietary polymer materials and products for a broad range of applications. The company designs proprietary molecular structures and polymer compounds for a broad range of electro-optic, bioscience, RF and specialty nanotechnology applications. The company also has developed proprietary processes for fabricating such devices. Lumera Corp. is headquartered in Bothell, WA. | 7 years |
| James McArthur | M | 62 |
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | 6 years |
| Vivek Rajgarhia | M | 56 | - | |
| Marc Correa | M | - | - | |
| Linda R. Judge | F | - |
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | 3 years |
| Karin Jooss | M | 59 |
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | 8 years |
| Thomas D. Mino | M | 77 |
Lumera Corp.
Lumera Corp. Packaged SoftwareTechnology Services Lumera Corp. develops proprietary polymer materials and products for a broad range of applications. The company designs proprietary molecular structures and polymer compounds for a broad range of electro-optic, bioscience, RF and specialty nanotechnology applications. The company also has developed proprietary processes for fabricating such devices. Lumera Corp. is headquartered in Bothell, WA. | 6 years |
| Nancy M. Crowell | F | 75 |
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | 9 years |
| Ron Shelton | M | 62 | 2 years | |
| James Fraser Black | M | 64 |
Lumera Corp.
Lumera Corp. Packaged SoftwareTechnology Services Lumera Corp. develops proprietary polymer materials and products for a broad range of applications. The company designs proprietary molecular structures and polymer compounds for a broad range of electro-optic, bioscience, RF and specialty nanotechnology applications. The company also has developed proprietary processes for fabricating such devices. Lumera Corp. is headquartered in Bothell, WA. | 4 years |
| Michael W. Ramsay | M | 67 |
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | 6 years |
| Peter K. Working | M | 75 |
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | 7 years |
| Carol C. Grundfest | F | 69 |
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | 8 years |
| Todd R. McIntyre | M | 60 |
Lumera Corp.
Lumera Corp. Packaged SoftwareTechnology Services Lumera Corp. develops proprietary polymer materials and products for a broad range of applications. The company designs proprietary molecular structures and polymer compounds for a broad range of electro-optic, bioscience, RF and specialty nanotechnology applications. The company also has developed proprietary processes for fabricating such devices. Lumera Corp. is headquartered in Bothell, WA. | - |
| Daniel C. Lykken | M | 70 |
Lumera Corp.
Lumera Corp. Packaged SoftwareTechnology Services Lumera Corp. develops proprietary polymer materials and products for a broad range of applications. The company designs proprietary molecular structures and polymer compounds for a broad range of electro-optic, bioscience, RF and specialty nanotechnology applications. The company also has developed proprietary processes for fabricating such devices. Lumera Corp. is headquartered in Bothell, WA. | 4 years |
| Michael Norinsberg | M | - |
Lumera Corp.
Lumera Corp. Packaged SoftwareTechnology Services Lumera Corp. develops proprietary polymer materials and products for a broad range of applications. The company designs proprietary molecular structures and polymer compounds for a broad range of electro-optic, bioscience, RF and specialty nanotechnology applications. The company also has developed proprietary processes for fabricating such devices. Lumera Corp. is headquartered in Bothell, WA. | - |
| Richard Serbin | M | 79 | 1 years | |
| Peter Biere | M | 67 | - | |
| Robert J. Dow | M | 73 |
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | 3 years |
| Robert H. Tidwell | M | 80 |
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | 9 years |
| Jeffrey Steven Silverman | M | - |
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | 2 years |
| Sanjiv Sam Gambhir | M | 61 |
Lumera Corp.
Lumera Corp. Packaged SoftwareTechnology Services Lumera Corp. develops proprietary polymer materials and products for a broad range of applications. The company designs proprietary molecular structures and polymer compounds for a broad range of electro-optic, bioscience, RF and specialty nanotechnology applications. The company also has developed proprietary processes for fabricating such devices. Lumera Corp. is headquartered in Bothell, WA. | 1 years |
| Wayne M. Perry | M | 74 |
Lumera Corp.
Lumera Corp. Packaged SoftwareTechnology Services Lumera Corp. develops proprietary polymer materials and products for a broad range of applications. The company designs proprietary molecular structures and polymer compounds for a broad range of electro-optic, bioscience, RF and specialty nanotechnology applications. The company also has developed proprietary processes for fabricating such devices. Lumera Corp. is headquartered in Bothell, WA. | - |
| Bob Ratliffe | M | - |
Lumera Corp.
Lumera Corp. Packaged SoftwareTechnology Services Lumera Corp. develops proprietary polymer materials and products for a broad range of applications. The company designs proprietary molecular structures and polymer compounds for a broad range of electro-optic, bioscience, RF and specialty nanotechnology applications. The company also has developed proprietary processes for fabricating such devices. Lumera Corp. is headquartered in Bothell, WA. | 8 years |
| Dale G. Ando | M | 70 |
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | 7 years |
| Dennis L. Winger | M | 77 |
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | 5 years |
| Thomas Shenk | M | 77 |
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | 8 years |
| Robert J. Petcavich | M | 70 |
Lumera Corp.
Lumera Corp. Packaged SoftwareTechnology Services Lumera Corp. develops proprietary polymer materials and products for a broad range of applications. The company designs proprietary molecular structures and polymer compounds for a broad range of electro-optic, bioscience, RF and specialty nanotechnology applications. The company also has developed proprietary processes for fabricating such devices. Lumera Corp. is headquartered in Bothell, WA. | - |
| Natalie Sacks | M | 59 |
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | 7 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 49 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Joseph J. Vallner
- Personal Network
